Patent evergreening: technological advancement and abusive commercial practices. Availability of essential medicine in the case of access to insulin
View/ Open
Publisher
DOI
10.26494/QMLJ3941
Metadata
Show full item recordAbstract
The article analyses problems caused by patent evergreening in the pharmaceutical
industry, with a particular focus on access to insulin. It points out how abusive commercial
practices prevent the most vulnerable to benefit from scientific developments of the modern world
and evidence-based medicine. This article does not only examine crucial legal aspects, such as a
coexistence of fundamental human rights and the TRIPS Agreement, but also considers the impact
of the patent system’s procedural norms. Finally, the article argues how secondary patenting
prevents the harmonisation of public interest and the enforcement of private rights, where
safeguarding equal access to essential medicine is required.
Authors
Radelli, MartaCollections
- Queen Mary Law Journal [38]
- Queen Mary Law Journal [38]
Licence information
Copyright statements
The following license files are associated with this item: